Masimo smartSET Receives FDA Clearance for New AFib and OIRD Alerts

Masimo announced FDA 510(k) clearance for its smartSET™ platform, adding atrial fibrillation (AFib) detection and opioid-induced respiratory depression (OIRD) monitoring to its pulse oximetry suite.

Regulatory Milestone Expands Clinical Toolkit

The clearance covers two algorithms that run inside the existing smartSET workflow. One algorithm flags irregular heart rhythms that match AFib. The second identifies respiratory patterns that suggest OIRD. Both functions work in real time on Masimo’s pulse oximetry hardware. Masimo filed the 510(k) package in early 2026. The FDA review examined algorithm safety, false-positive rates, and compatibility with hospital information systems. The agency concluded that the device meets the required standards for clinical use. Embedding the algorithms directly into the oximeter lets clinicians receive alerts without separate monitoring equipment. This follows Masimo’s earlier OIRD detection clearance in 2024.

Potential Impact on Patient Management

Bedside AFib detection could shorten the time between rhythm onset and treatment. Early identification may reduce the need for invasive diagnostics in stable patients. OIRD monitoring aims to catch respiratory compromise before hypoxia develops. In procedural settings, the alert can prompt dose adjustment or reversal agents, potentially lowering adverse-event rates. Both alerts appear on the smartSET dashboard, where nurses view trend graphs and acknowledge notifications. The unified interface reduces alarm fatigue by consolidating data streams. Hospitals already using Masimo’s SET® pulse oximetry can adopt the new features with a software update. No hardware replacement is required.

Market Reception and Competitive Context

Pilot sites report that clinicians value the added diagnostic insight. An ICU director said the AFib alert helped start anticoagulation earlier than usual. The new alerts place Masimo alongside other vendors expanding beyond basic SpO₂ measurement. Masimo’s reputation for low-motion artifact performance may give it an edge in high-acuity environments. Analysts note that the combined AFib and OIRD capabilities could make smartSET more attractive to health systems seeking bundled monitoring solutions. The move may influence procurement decisions where bundled pricing matters.

Outlook for Adoption and Future Development

Masimo plans a phased software rollout to existing customers. The company expects broader adoption in the United States during the first half of 2027. Future updates may add modules for early sepsis detection or hemodynamic instability alerts. Expanding the algorithm suite could deepen the platform’s role in continuous patient monitoring. Regulatory pathways for AI-enabled medical devices remain under discussion. Masimo’s clearance may serve as a reference point for other manufacturers pursuing similar integrations. Stakeholders should watch real-world performance data as hospitals implement the new alerts. Early evidence on false-positive rates and clinical outcomes will shape the perceived value of the enhanced pulse oximetry platform.